BioCentury
ARTICLE | Clinical News

Ziconotide neuronal N-type calcium channel blocker regulatory update

December 18, 2000 8:00 AM UTC

DRAX submitted an NDS for Canadian approval of Ziconotide to treat chronic intractable pain associated with advanced cancer, HIV infection or trauma. The product has priority review status in Canada. ...